SciELO - Scientific Electronic Library Online

 
vol.86 número12 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Archivos de la Sociedad Española de Oftalmología

versión impresa ISSN 0365-6691

Resumen

GREGORI-GISBERT, I. et al. Recurrent and chronic central serous chorioretinopathy: Retina thickness evaluation one month after intravitreal bevacizumab injection. Arch Soc Esp Oftalmol [online]. 2011, vol.86, n.12, pp.407-411. ISSN 0365-6691.

Purpose: To evaluate the efficacy of intavitreal injection of bevacizumab in patients with chronic central serous chorioretinopathy. Methods: A study of 8 patients with central serous chorioretinopathy who were treated with intravitreal injection of bevacizumab. We studied the visual acuity with Snellenns method and the foveal thickness, before and after the injection. Results: The mean age of the patients was 50.25 years. After one month of follow-up, visual acuity before the injection was 0.431±0.249 vision lines and after was 0.631±0.310 vision lines (P=.017). The foveal thickness was 351.25±78.492μm and after treatment was 183.50±22.640μm (P=.012). Conclusions: Intravitreal bevacizumab can be an alternative treatment in patients with serous central chorioretinopathy as it leads to a better objective visual acuity and foveal thickness with optical coherence tomography.

Palabras clave : Bevacizumab; Central serous chorioretinopathy.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons